| Literature DB >> 9222866 |
K Nakajima1, T Saito, A Tamura, M Suzuki, T Nakano, M Adachi, A Tanaka, N Tada, H Nakamura, T Murase.
Abstract
Type III is a remnant hyperlipoproteinemia identified by the presence of beta-VLDL (remnant lipoprotein) as well as a genetic variant of apo E (apo E2/2). The RLP isolated from the serum of Type III patients by a new method we have developed, the RLPcholesterol assay, was identified as chylomicron and VLDL remnant. In addition, the RLP-C levels of the Type III patients were significantly higher than other hyperlipidemic patients with similar serum TG levels, while the ratio of TC/TG in RLP-C of both groups was not significantly different. The RLP-cholesterol assay appears to be useful for the screening and monitoring of Type III hyperlipoproteinemia when used in conjunction with the assays of serum TG level and genetic apo E isoform analysis.Entities:
Mesh：
Substances：
Year: 1994 PMID： 9222866 DOI： 10.5551/jat1994.1.30
Source DB: PubMed Journal: J Atheroscler Thromb ISSN： 1340-3478 Impact factor: 4.928